Dose Modification Strategies in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, Dr. Devarakonda asks Dr. Rotow to address the role of dose interruptions and reductions in managing treatment related toxicities in EGFR mutated metastatic non-small cell lung cancer. Dr. Rotow emphasizes that dose modification is a common and appropriate strategy in long term targeted therapy, particularly when dermatologic or other class related adverse events affect quality of life. She highlights the importance of early intervention rather than allowing toxicity to escalate to severe levels.

The discussion references clinical trial data suggesting that temporary dose interruptions or reductions do not necessarily compromise progression free survival, providing reassurance to clinicians concerned about maintaining efficacy. The panel underscores that treatment for EGFR mutated metastatic non-small cell lung cancer is a marathon rather than a sprint, and thoughtful dose adjustments can help patients remain on therapy safely. This segment reinforces that preserving tolerability and functional status is central to sustaining long term disease control.